These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 10911502)
1. [Development of new drugs--the United States regulatory perspective, 1998]. Averbuch M; Levo Y Harefuah; 1998 Dec; 135(12):638-40. PubMed ID: 10911502 [No Abstract] [Full Text] [Related]
2. Aerosolized drugs: current regulatory perspective. Chew N Respir Care; 2000 Jun; 45(6):764-8. PubMed ID: 10894466 [TBL] [Abstract][Full Text] [Related]
3. Pediatric drug development in anesthesiology: an FDA perspective. Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624 [No Abstract] [Full Text] [Related]
4. Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: formulating recommendations in an environment of evolving clinical science. Shames D; Monroe SE; Davis D; Soule L Int J Impot Res; 2007; 19(1):30-6. PubMed ID: 16728969 [TBL] [Abstract][Full Text] [Related]
5. Radiopharmaceuticals and FDA: a clinician's perspective. Siegel BA Med Instrum; 1981; 15(6):355-60. PubMed ID: 7040923 [No Abstract] [Full Text] [Related]
6. A few thoughts on the development and regulation of neuropeptides. Gueriguian JL; Chiu YY NIDA Res Monogr; 1986; 70():405-14. PubMed ID: 3093883 [No Abstract] [Full Text] [Related]
8. EU law mandates drug testing in children. Sinha G J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609 [No Abstract] [Full Text] [Related]
9. Drug studies in children. Finkel MJ Pediatr Pharmacol (New York); 1980; 1(1):7-14. PubMed ID: 7346734 [No Abstract] [Full Text] [Related]
13. Changing requirements for evaluation of pharmacologic agents. Chesney RW; Christensen ML Pediatrics; 2004 Apr; 113(4 Suppl):1128-32. PubMed ID: 15060209 [TBL] [Abstract][Full Text] [Related]
14. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
15. No relaxation on drug safety and efficacy. Russell AS; Grace M World Health Forum; 1993; 14(1):31-3. PubMed ID: 8439367 [TBL] [Abstract][Full Text] [Related]
16. [Legal liability and insurance questions regarding the testing of drugs, in particular with regard to the new drug law of 1976]. Granitza A Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1978; 19():78-83. PubMed ID: 362173 [No Abstract] [Full Text] [Related]
17. Are development times for pharmaceuticals increasing or decreasing? Keyhani S; Diener-West M; Powe N Health Aff (Millwood); 2006; 25(2):461-8. PubMed ID: 16522587 [TBL] [Abstract][Full Text] [Related]
18. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
19. Psychopharmacology. The medication merry-go-round. Brown K Science; 2003 Mar; 299(5613):1646-9. PubMed ID: 12637713 [No Abstract] [Full Text] [Related]